| Literature DB >> 29653869 |
E Lababidi1, O Breik2, J Savage2, H Engelbrecht2, R Kumar2, C W Crossley2.
Abstract
Chronic therapy with the new direct oral anticoagulants (DOACs) poses new challenges for dental practitioners assessing the risk versus benefit of cessation versus non-cessation of anticoagulant therapy for dentoalveolar procedures. A retrospective controlled cohort study was designed to evaluate a non-cessation protocol for patients taking DOACs in the setting of dental extractions. A records review covering the period 1 January 2016 to 31 December 2016 identified 43 patients on DOAC therapy; 53 dentoalveolar procedures were performed under local anaesthesia, of which 15 included varying degrees of peri-procedural cessation. A control group of 50 patients on uninterrupted warfarin therapy undergoing 59 dentoalveolar procedures was identified. The incidence, severity, and timing of bleeding events were recorded for each group. Four (10.5%) minor bleeding events were recorded in the non-cessation DOAC group and nine (15.3%) minor bleeding events in the warfarin group. No bleeding events were recorded in the DOAC cessation group. Comparison of the incidence of bleeding events between the non-cessation DOAC group and the warfarin group showed no statistically significant difference (odds ratio 0.65, P=0.56). Within the limitations of this study, dental extractions in the context of continuing DOAC therapy can be performed safely provided extra local haemostatic measures are applied.Entities:
Keywords: DOAC; NOAC; dentoalveolar surgery; direct oral anticoagulants; novel oral anticoagulants
Mesh:
Substances:
Year: 2018 PMID: 29653869 DOI: 10.1016/j.ijom.2018.03.009
Source DB: PubMed Journal: Int J Oral Maxillofac Surg ISSN: 0901-5027 Impact factor: 2.789